Needham: Reiterated the BioCryst Pharma (BCRX.US) rating, adjusted from buy to buy rating, target price of $12.00.
Zhitong FinanceApr 10 19:11
BioCryst Pharma Analyst Ratings
BenzingaApr 10 19:08
Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
BenzingaApr 10 19:10
Buy Rating Affirmed for BioCryst Pharmaceuticals on Orladeyo's Success and Strong Growth Prospects
TipRanksFeb 27 00:25
Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
BenzingaJan 8 18:52
BioCryst Pharma Analyst Ratings
BenzingaJan 8 18:50
Komo: Six major biotech stocks including Insmed (INSM.US) are rated for “increase in holdings”
Zhitong FinanceNov 27, 2023 08:16
JP Morgan Reinstates Overweight on BioCryst Pharma, Announces $10 Price Target
BenzingaNov 20, 2023 21:15
BioCryst Pharma Analyst Ratings
BenzingaNov 20, 2023 21:14
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)
TipRanksNov 9, 2023 09:47
BioCryst Pharmaceuticals' Promising Pipeline and Undervalued Stock: A Buy Rating Analysis
TipRanksNov 6, 2023 21:26
Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
BenzingaNov 6, 2023 19:33
BioCryst Pharma Analyst Ratings
BenzingaNov 6, 2023 19:32
RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target
BenzingaSep 26, 2023 00:01
BioCryst Pharma Analyst Ratings
BenzingaSep 26, 2023 00:00
RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10
BenzingaSep 18, 2023 19:16
BioCryst Pharma Analyst Ratings
BenzingaSep 18, 2023 19:16
HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target
BenzingaAug 4, 2023 18:14
BioCryst Pharma Analyst Ratings
BenzingaAug 4, 2023 18:13
Needham Reiterates Buy on BioCryst Pharma, Lowers Price Target to $12
BenzingaAug 4, 2023 01:27
No Data
No Data